Abstract 1570P
Background
Patients with Esophageal Cancer (EC) have variable responses to (chemo)radiotherapy. A reliable early prediction of outcomes allows for enhancing treatment efficacy and follow-up monitoring. DCE-MRI can provide information regarding tumor perfusion and permeability and has shown prognostic value in certain tumor types. Our aim was to investigate the potential application of DCE-MRI parameters as predictors for progression-free (PFS) and overall survival (OS) inpatients with EC treated with concurrent chemoradiation (CRT).
Methods
This study involved fifty-two patients with esophageal cancer and treated with CRT. The patients underwent DCE-MRI before CRT (pre-CRT) in three weeks and three weeks after starting CRT (post-CRT). Patients were grouped into high and low risk groups according to the cut-off value of best OS and PFS respectively. The correlations between quantitative parameters of DCE-MRI (pre-Ktrans, post-Ktrans and the changes and ratios of parameters (ΔiKtrans, riKtrans), and OS/PFS were calculated and compared between two-time frames in two groups, respectively. The K-M method was used to calculate the survival curve, and the log-rank method was used to compare differences in the survival curves.
Results
The level of pre-CRT Ktrans was positively associated with OS (cutoff value=70.53/min, p=0.113) and PFS (cutoff value=70.53/min, p=0.026). The level of post-CRT Ktrans was impaired associated with OS (cutoff value=45.60/min, p=0.001) and PFS (cutoff value=45.60/min, p=0.003). Level of riKtrans was impaired associated with OS (cutoff value=0.374, p=0.024) and PFS (cutoff value=0.374, p=0.040). The level of ΔiKtrans was impaired associated with OS (cutoff value=4.5/min, p=0.048) and PFS (cutoff value=0.595/min, p=0.056).
Conclusions
This study suggests an important role for DCE-MRI parameter Ktrans as a predictor of outcome in Esophageal Cancer patients treated with CRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Liu.
Funding
NA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22